TrialSignal
Clinical trial intelligence report
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 24, 2026
Report code
NCT03199586-Jun 24, 2026
NCT ID
NCT03199586
Status
COMPLETED
Phase
PHASE1
Sponsor
Novita Pharmaceuticals, Inc.
Executive brief
Investment-Ready Snapshot
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03199586
Indication
Breast Cancer
Modality
small molecule
Target
NP-G2-044
Intervention
NP-G2-044
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.